Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 12/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20811536 | 0.86 | PDE2A (0.55) | PDE2AGAANPSR1CYP1A2CYP2C9 | |
| SCHEMBL29453116 | 0.86 | PDE2A (0.55) | PDE2AGAANPSR1CYP1A2CYP2C9 | |
| SCHEMBL18358271 | 0.84 | PDE2A (0.55) | PDE2ACFTRMAPK1CYP1A2CYP2C9 | |
| SCHEMBL18097879 | 0.82 | PDE2A (0.53) | PDE2ACFTRGPR139GAANPSR1 | |
| SCHEMBL15670693 | 0.81 | CES2 (0.45) | GAACYP1A2CYP2C19IDO1 | |
| SCHEMBL20791346 | 0.81 | PDE2A (0.54) | PDE2AGAACYP1A2IDO1 | |
| SCHEMBL30525047 | 0.81 | PDE2A (0.54) | PDE2AGAACYP1A2IDO1 | |
| SCHEMBL30697596 | 0.80 | MEN1 (0.38) | CYP1A2 | |
| Hydrochloric Acid SCHEMBL28334116 | 0.80 | CES2 (0.44) | GAACYP1A2CYP2C19IDO1 | |
| SCHEMBL18358413 | 0.80 | PDE2A (0.48) | PDE2AGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| WO-2017003894-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017000277-A1 | SUBSTITUTED TRIAZOLO BICYCLICCOMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE3A, PDE4D | PDE2A 1/4885CFTR 2849/4885GPR139 1009/4885 |
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | PDE2A, PDE3A, PDE4D | PDE2A 1/4885CFTR 2849/4885GPR139 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.